Halozyme (NASDAQ: HALO) insider lines up new stock sale after recent disposals

Rhea-AI Filing Summary

Halozyme Therapeutics insider Helen Torley filed a Form 144 indicating a proposed sale of 240,000 shares of common stock through J.P. Morgan Securities LLC, with an aggregate market value of $23,678,400 as of 08/17/2026. The filing lists 113,498,000 shares of Halozyme common stock outstanding. It also reports prior sales during the past three months totaling 51,923 shares of common stock for aggregate proceeds of $3,523,398 across four transactions.

Key Figures

Proposed shares to be sold: 240,000 shares Aggregate market value of proposed sale: $23,678,400 Shares outstanding: 113,498,000 shares +5 more

8 metrics

Proposed shares to be sold 240,000 shares Common stock proposed for sale through J.P. Morgan Securities LLC

Aggregate market value of proposed sale $23,678,400 Value of 240,000 shares as of 08/17/2026

Shares outstanding 113,498,000 shares Halozyme common stock outstanding referenced in the Form 144

Shares sold 06/01/2026 20,000 shares Common stock sold by Helen Torley on 06/01/2026

Proceeds 06/01/2026 $1,351,606 Proceeds from 20,000-share sale on 06/01/2026

Shares sold 06/02/2026 20,000 shares Common stock sold by Helen Torley on 06/02/2026

Proceeds 06/02/2026 $1,327,748 Proceeds from 20,000-share sale on 06/02/2026

Shares sold 06/03/2026 10,000 shares Common stock sold by Helen Torley on 06/03/2026

Key Terms

Form 144, Securities To Be Sold, Stock Option Exercise, aggregate market value

4 terms

Form 144 regulatory

"Helen Torley filed a Form 144 indicating a proposed sale"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Securities To Be Sold regulatory

"144: Securities To Be Sold Common Stock"

Stock Option Exercise financial

"Common Stock | 08/17/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

aggregate market value financial

"with an aggregate market value of $23,678,400"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What does Halozyme Therapeutics (HALO) disclose in this Form 144 filing?

Halozyme Therapeutics discloses that Helen Torley plans to sell 240,000 shares of common stock through J.P. Morgan Securities LLC, with an aggregate market value of $23,678,400 as of 08/17/2026, under a Form 144 notice of proposed sale.

How many Halozyme (HALO) shares are proposed to be sold and through which broker?

The filing reports a proposed sale of 240,000 shares of Halozyme common stock through J.P. Morgan Securities LLC. These shares are to be sold on or after 08/17/2026 on the NASDAQ market, according to the Form 144 disclosure.

What is the reported market value of the Halozyme (HALO) shares to be sold?

The Form 144 lists an aggregate market value of $23,678,400 for the 240,000 shares of Halozyme common stock proposed for sale. This value is tied to the planned sale date of 08/17/2026 as disclosed in the securities information section.

How many Halozyme (HALO) shares were sold by Helen Torley in the past 3 months?

The filing reports that Helen Torley sold a total of 51,923 shares of Halozyme common stock in the past three months. These consisted of 20,000 shares on 06/01/2026, 20,000 on 06/02/2026, 10,000 on 06/03/2026, and 1,923 on 07/08/2026.

What were the proceeds from Helen Torley’s recent Halozyme (HALO) stock sales?

The reported proceeds from recent sales total $3,523,398 across four transactions. These are $1,351,606 on 06/01/2026, $1,327,748 on 06/02/2026, $690,653 on 06/03/2026, and $153,391 on 07/08/2026, all for Halozyme common stock.

How many Halozyme (HALO) shares are outstanding according to this Form 144?

The Form 144 indicates that there are 113,498,000 shares of Halozyme Therapeutics common stock outstanding. This figure provides context for the proposed sale of 240,000 shares, which represents only a portion of the total shares outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 05:16 PM Accepted by SEC EDGAR 08/17/2026 - 05:16 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 270 Park Avenue, 10th Floor New York NY 10017	240000	23678400	113498000	08/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/17/2026	Stock Option Exercise	Issuer			240000	08/17/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	06/01/2026	20000	1351606
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	06/02/2026	20000	1327748
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	06/03/2026	10000	690653
Helen Torley C/o Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Common Stock	07/08/2026	1923	153391

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)